Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

American Journal of Hematology

Volumn 91, Issue 7, 2016, Pages 661-665

  Pastores, Gregory M ^a   Shankar, Suma P ^b   Petakov, Milan ^c   Giraldo, Pilar ^d   Rosenbaum, Hanna ^e   Amato, Dominick J ^f   Szer, Jeffrey ^g   Chertkoff, Raul ^h   Brill Almon, Einat ^h   Zimran, Ari ⁱ  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF BELGRADE   (Serbia)

^d HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^e RAMBAM MEDICAL CENTER   (Israel)

^f MOUNT SINAI HOSPITAL   (Canada)

^g ROYAL MELBOURNE HOSPITAL   (Australia)

^h Protalix Biotherapeutics   (Israel)

ⁱ SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CHITOTRIOSIDASE; IMIGLUCERASE; TALIGLUCERASE ALFA;

ADULT; ARTICLE; CLINICAL ARTICLE; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ACTIVITY; ENZYME REPLACEMENT; FEVER; GAUCHER DISEASE; HEMOGLOBIN DETERMINATION; HUMAN; KNEE OSTEOARTHRITIS; KNEE PAIN; LIVER WEIGHT; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SPLEEN; THROMBOCYTE COUNT; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 84973870936     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.24399     Document Type: Article

References (14)

1. Grabowski GA, Petsko GA, Kolodny EH. Gaucher disease. In: Valle D, Beaudet AL, Vogelstein B, et al., editors. The Online Metabolic and Molecular Basis of Inherited Disease. New York, NY: The McGraw Hill Companies, Inc.; 2010. Chapter 146.
2. Grabowski GA, Kolodny EH, Weinreb NJ, et al. Gaucher disease: Phenotypic and genetic variation. In: Valle D, Beaudet AL, Vogelstein B, et al., editors. The Online Metabolic and Molecular Bases of Inherited Disease. New York, NY: The McGraw Hill Companies, Inc.; 2010. Chapter 146.1.
3. Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency―macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991;324:1464–1470.
4. Hollak CE, vom Dahl S, Aerts JM, et al. Force majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010;44:41–47.
5. Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: A history and perspective. Drug Des Dev Ther 2012;6:81–106.
6. Fox JL. First plant-made biologic approved. Nat Biotechnol 2012;30:472.
7. Grabowski GA, Golembo M, Shaaltiel Y. Taliglucerase alfa: An enzyme replacement therapy using plant cell expression technology. Mol Genet Metab 2014;112:1–8.
8. National Institutes of Health. Switchover trial from imiglucerase to plant cell expressed recombinant human glucocerebrosidase [NCT00712348]. June 10, 2013; Available at: http://clinicaltrials.gov/ct2/show/NCT00712348?term=nct00712348&rank=1. Accessed: January 27, 2015.
9. Pastores GM, Petakov M, Giraldo P, et al. A phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase. Blood Cells Mol Dis 2014;53:253–260.
10. National Institutes of Health. Plant cell expressed recombinant human glucocerebrosidase extension trial [NCT00705939]. August 13, 2013; Available at: http://clinicaltrials.gov/ct2/show/NCT00705939?term=nct00705939&rank=1. Accessed: October 8, 2015.
11. Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood 2011;118:5767–5773.
12. Bracoud L, Ahmad H, Brill-Almon E, Chertkoff R. Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model. Blood Cells Mol Dis 2011;46:47–52.
13. Pastores GM, Weinreb NJ, Aerts H, et al. Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 2004;41:4–14.
14. Elelyso [package insert]. New York, NY: Pfizer Labs; 2015.